Franklin Resources Inc. Buys 5,687 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Franklin Resources Inc. lifted its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 5.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 104,141 shares of the company’s stock after acquiring an additional 5,687 shares during the quarter. Franklin Resources Inc. owned approximately 0.17% of Health Catalyst worth $857,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after buying an additional 66,896 shares during the last quarter. Zacks Investment Management grew its position in shares of Health Catalyst by 6.7% in the third quarter. Zacks Investment Management now owns 296,121 shares of the company’s stock valued at $2,410,000 after purchasing an additional 18,677 shares during the last quarter. State Street Corp lifted its holdings in shares of Health Catalyst by 2.5% during the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after buying an additional 28,251 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Health Catalyst during the 3rd quarter worth approximately $84,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of Health Catalyst by 69.4% in the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after buying an additional 211,805 shares during the period. 85.00% of the stock is owned by institutional investors.

Health Catalyst Stock Performance

HCAT opened at $7.08 on Monday. The company has a market cap of $430.80 million, a price-to-earnings ratio of -5.24 and a beta of 1.31. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company’s fifty day moving average price is $7.96 and its two-hundred day moving average price is $7.48.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.22) earnings per share. On average, analysts expect that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on HCAT shares. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. JPMorgan Chase & Co. increased their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Stephens upped their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Evercore ISI boosted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus price target of $11.79.

Insider Buying and Selling

In other news, Director Duncan Gallagher sold 4,500 shares of Health Catalyst stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the transaction, the director now directly owns 74,438 shares in the company, valued at approximately $519,577.24. The trade was a 5.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jason Alger sold 19,599 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now directly owns 86,712 shares in the company, valued at $721,443.84. This trade represents a 18.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,051 shares of company stock worth $563,515. Insiders own 2.50% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.